J A Corless1, C J Warburton. 1. Aintree Chest Centre, University Hospital, Aintree, Aintree Chest Centre, University Hospital Aintree, Lower Lane, Liverpool, Merseyside, UK, L9 7AL. j.corless@bigfoot.com
Abstract
BACKGROUND: Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis. OBJECTIVES: To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage). SEARCH STRATEGY: The Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk* SELECTION CRITERIA: Only randomised, controlled trials were considered DATA COLLECTION AND ANALYSIS: The results of searches were analysed by both authors MAIN RESULTS: No randomised, controlled trials were identified REVIEWER'S CONCLUSIONS: Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.
BACKGROUND: Leukotriene receptor antagonists are a new class of drug that were initially identified for use in asthma. As they have an effect on neutrophil mediated inflammation, they may be of benefit in bronchiectasis. OBJECTIVES: To determine whether leukotriene receptor antagonists have any additive benefit over and above conventional treatment for bronchiectasis (usually consisting of antibiotics and postural drainage). SEARCH STRATEGY: The Cochrane Airways Group clinical trials register derived from MEDLINE, EMBASE and hand searching of major journals was searched using the terms:Bronchiec* AND leukotrien* OR anti-leuk* OR cysteinyl, Bronchiec* AND monteluk*, Bronchiec* AND zafirluk* SELECTION CRITERIA: Only randomised, controlled trials were considered DATA COLLECTION AND ANALYSIS: The results of searches were analysed by both authors MAIN RESULTS: No randomised, controlled trials were identified REVIEWER'S CONCLUSIONS: Further research is required to establish any benefit from the use of leukotriene antagonists in bronchiectasis.
Authors: Chris D Bailey; Richard Wagland; Rasha Dabbour; Ann Caress; Jaclyn Smith; Alex Molassiotis Journal: BMC Pulm Med Date: 2010-12-09 Impact factor: 3.317
Authors: Hamdan Al-Jahdali; Abdullah Alshimemeri; Abdullah Mobeireek; Amr S Albanna; Nehad N Al Shirawi; Siraj Wali; Khaled Alkattan; Abdulrahman A Alrajhi; Khalid Mobaireek; Hassan S Alorainy; Mohamed S Al-Hajjaj; Anne B Chang; Stefano Aliberti Journal: Ann Thorac Med Date: 2017 Jul-Sep Impact factor: 2.219